Dormant tumour cells that survive initial therapy can awaken years later to seed metastases. New data from a phase II trial indicate that intercepting this dormancy by targeting autophagy and mTOR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback